- Ọgwụgwọ
- Ihe akaebe
- Neuroblastoma
- Ọrịa siri ike
- Ihe akaebe
- TILS
- Ọgwụgwọ NK Cell
- Myasthenia Gravis (MG)
- Ọrịa kansa ọbara Lymphoblastic dị oke njọ (B-ALL)
- Ọrịa Lupus Erythematosus Sistemụ (SLE)
- Ọrịa kansa ọbara Lymphoblastic dị oke njọ (T-ALL)
- Ọrịa Lymphoma na-abụghị Hodgkin (NHL)
- Ọtụtụ Myeloma (MM)
- Lymphom B-cell buru ibu nke gbasaara agbasa
- Ọrịa kansa ọbara B-lymphocytic
- Myeloma
Ọrịa kansa ọbara Lymphoblastic dị oke njọ (T-ALL)-07
Nwa agbọghọ Miao na-enweta mgbaghara zuru oke mgbe ọgwụgwọ CAR-T gasịrị mgbe e mechasịrị ịwa ahụ ọzọ.
Amei, nwa akwụkwọ gụsịrị akwụkwọ na mahadum si Hunan nke agbụrụ Miao, bipụtara akwụkwọ SCI abụọ. Na Eprel 2, 2020, a kpọbatara ya n'ụlọ ọgwụ mpaghara n'ihi ahụ ọkụ na-aga n'ihu. Nnyocha ụmị ọkpụkpụ chọpụtara na ọ nwere ọrịa leukemia lymphoblastic (T-ALL). Mgbe ọ gachara ọtụtụ usoro ọgwụgwọ chemotherapy n'ụlọ ọgwụ dị n'èzí, ụmị ọkpụkpụ ya ka nọ na-agbaghara. Na Nọvemba 2, 2020, e mere ya mgbanwe mkpụrụ ndụ hematopoietic allogeneic n'ụlọ ọgwụ anyị (nwanne na nwanne, HLA 7/10 match). Mgbe e tinyere ya n'ime ọbara, e tinyere mkpụrụ ndụ ahụ nke ọma, nyocha ndị ọzọ gosiri na ọ na-ebelata.
Na Juun 16, 2021 (ọnwa asaa mgbe e tinyere ya n'ọrụ), nyocha emere mgbe niile gosiri na ọrịa leukemia ya amalitela ọzọ. Ọgwụgwọ maka ọgwụgwọ kansa ọbara nke mechara achịkwaghị ọrịa ahụ, o wee nwee ọrịa pneumonia na herpes virus, ọnya ọnụ na-egbu mgbu nke mere ka ọ ghara ilo ihe. E tinyere ya n'ụlọ ọgwụ nke abụọ nke ngalaba hematology ma debanye aha ya na nnwale ahụike CD7 CAR-T.
Ndị otu ahụike nyere ọgwụgwọ dị irè megide ọrịa, belata ihe mgbu, na ọbara na platelet dị ukwuu. N'ihi oke ibu nke etuto ahụ (80% mgbawa n'ime ụmị ọkpụkpụ na 97% mgbawa n'ime ọbara dị n'akụkụ), ọ gaghị ekwe omume ịchịkọta mkpụrụ ndụ ya. A chịkọtara lymphocytes ọbara dị n'akụkụ site n'aka onye nyere onyinye (nwanne ya nwoke) ma ziga ya na ụlọ ọrụ biotech maka ọdịbendị mkpụrụ ndụ CAR-T.
Na Ọgọst 10, 2021, e tinyere mkpụrụ ndụ CAR-T CD7 nke ndị nyere onyinye ọzọ. Mgbe e tinyere mkpụrụ ndụ CAR-T ọzọ, mkpụrụ ndụ CAR-T gbasaara ruo 54.64% n'ọbara dị n'akụkụ, naanị ahụ ọkụ na enweghị ọrịa cytokine release syndrome (CRS) ma ọ bụ ọrịa graft-versus-host (GVHD). Nnyocha ụmị ọkpụkpụ n'ụbọchị nke 16 mgbe e tinyere mkpụrụ ndụ CAR-T ọzọ gosiri mgbaghara zuru oke, yana 54.13% mkpụrụ ndụ CAR-T n'ime ụmị ọkpụkpụ. Na ụbọchị nke 36, ụmị ọkpụkpụ nọgidere na-egosi mgbaghara na-adịgide adịgide. Ugbu a, ọnọdụ uche ya, ụra ya, na agụụ ya dị mma, ọ na-agbakekwa nke ọma.
nkọwa2
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

